HomeGOVX • NASDAQ
add
Geovax Labs Inc
Previous close
$1.92
Day range
$1.75 - $1.91
Year range
$1.09 - $11.18
Market cap
15.26M USD
Avg Volume
801.22K
P/E ratio
-
Dividend yield
-
Primary exchange
NASDAQ
Market news
Financials
Income Statement
Revenue
Net income
| (USD) | Jun 2024info | Y/Y change |
|---|---|---|
Revenue | 300.68K | — |
Operating expense | 1.09M | -25.57% |
Net income | -5.06M | 14.57% |
Net profit margin | -1.68K | — |
Earnings per share | — | — |
EBITDA | -5.04M | 18.23% |
Effective tax rate | — | — |
Balance Sheet
Total assets
Total liabilities
| (USD) | Jun 2024info | Y/Y change |
|---|---|---|
Cash and short-term investments | 1.56M | -91.22% |
Total assets | 4.10M | -80.73% |
Total liabilities | 6.40M | 56.76% |
Total equity | -2.31M | — |
Shares outstanding | 5.26M | — |
Price to book | -3.49 | — |
Return on assets | -339.60% | — |
Return on capital | 1,198.07% | — |
Cash Flow
Net change in cash
| (USD) | Jun 2024info | Y/Y change |
|---|---|---|
Net income | -5.06M | 14.57% |
Cash from operations | -1.94M | 67.85% |
Cash from investing | — | — |
Cash from financing | 2.73M | — |
Net change in cash | 792.85K | 113.08% |
Free cash flow | -273.26K | 93.08% |
About
GeoVax is a clinical-stage biotechnology company which develops vaccines. GeoVax's development platform uses Modified Vaccinia Ankara vector technology, with improvements to antigen design and manufacturing capabilities. GeoVax uses recombinant DNA or recombinant viruses to produce virus-like particles in the person being vaccinated. Wikipedia
Founded
1988
Headquarters
Website
Employees
17
